Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA

• Main Authors: Daniel A. Barocas, Denise R. Globe, Danielle C. Colayco, Ahunna Onyenwenyi, Amanda S. Bruno, Thomas J. Bramley, Rachel J. Spear
• Format: Article
• Language: English
• Published: Hindawi Limited 2012-01-01
• Series: Advances in Urology
• Online Access: http://dx.doi.org/10.1155/2012/421709

Seventy percent of newly diagnosed bladder cancers are classified as non-muscle-invasive bladder cancer (NMIBC) and are often associated with high rates of recurrence that require lifelong surveillance. Currently available treatment options for NMIBC are associated with toxicities that limit their use, and actual practice patterns vary depending upon physician and patient characteristics. In addition, bladder cancer has a high economic and humanistic burden in the United States (US) population and has been cited as one of the most costly cancers to treat. An unmet need exists for new treatment options associated with fewer complications, better patient compliance, and decreased healthcare costs. Increased prevention of recurrence through greater adherence to evidence-based guidelines and the development of novel therapies could therefore result in substantial savings to the healthcare system.